REX Peptide ETF (NASDAQ:PEPT – Get Free Report) saw a large increase in short interest in the month of October. As of October 30th, there was short interest totaling 8,874 shares, an increase of 3,844.0% from the October 15th total of 225 shares. Approximately 7.4% of the company’s shares are short sold. Based on an average daily volume of 7,975 shares, the days-to-cover ratio is currently 1.1 days.
REX Peptide ETF Stock Performance
NASDAQ:PEPT opened at $27.71 on Wednesday. REX Peptide ETF has a 12-month low of $25.06 and a 12-month high of $28.14. The firm has a market capitalization of $3.33 million and a PE ratio of 6,423.27.
REX Peptide ETF (NASDAQ: PEPT) is an exchange-traded fund designed to provide targeted exposure to companies involved in the development, production, and commercialization of peptide-based medicines and related technologies. Rather than operating as a traditional company, the fund holds a portfolio of businesses participating in the broader peptide therapeutics industry. The fund’s investment focus may include pharmaceutical and biotechnology companies developing peptide treatments, as well as businesses supporting peptide research, drug discovery, manufacturing, delivery systems, and related healthcare applications.
See Also
- Five stocks we like better than REX Peptide ETF
- Anthropic’s Trillion-Dollar IPO Could Give Cloud Giants a Double Win
- The AI Debt Bill Is Coming Due, But Biotech Has Revenue to Show for the Boom
- 3 Insider Selling Stories; 3 Different Signals for Investors
- The Trade Desk Beats on Revenue, But the Fine Print Matters
Receive News & Ratings for REX Peptide ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REX Peptide ETF and related companies with MarketBeat.com's FREE daily email newsletter.
